Immediately following the third phase in 2020, more attention was paid to the feasibility of NLRP3 inflammasome as a therapeutic target, so keywords regarding the evaluation of the efficacy to treat diseases became popular, such as “functional recovery” and “cognitive impairment”. This evidence concerns the gene NLRP3 and Cognitive impairment.